Company / Return on Equity (ROE)
Sonoma Pharmaceuticals, Inc. Return on Equity (ROE) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-78.8%
FY2025
5-year range
-78.8% / -58.5%
FY2021-FY2025
Trend
-22.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Sonoma Pharmaceuticals, Inc. reports negative total equity of -78.8% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-78.8% in FY2025 with a 5-year CAGR of +33.7%.
Declined from -58.5% to -78.8% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -5.1pp
- 5-Year Change
- +33.7pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 22.0% year-over-year.
- Peak return on equity (roe) was recorded in FY2018.
- Lowest return on equity (roe) in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2026 | - | - |
| FY2025 | -78.8% | -22.0% |
| FY2024 | -64.6% | -10.4% |
| FY2023 | -58.5% | +20.6% |
| FY2022 | -73.7% | -25.2% |
| FY2021 | -58.8% | +47.7% |
| FY2020 | -112.5% | -20.3% |
| FY2019 | -93.5% | -316.1% |
| FY2018 | 43.3% | +143.2% |
| FY2017 | -100.2% | -47.3% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026